- Home
- FSK vs SLNO Comparison
FSK vs SLNO Comparison
Compare FSK & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSK | SLNO |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FSK | SLNO |
|---|---|---|
| Price | $11.03 | $53.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $13.19 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 3.5M | 1.8M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 18.82% | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.59 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | N/A | $150.46 |
| Revenue Next Year | N/A | $50.37 |
| P/E Ratio | ★ N/A | $89.81 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $9.72 | $29.43 |
| 52 Week High | $22.68 | $89.12 |
Technical Indicators
Market Signals| Indicator | FSK | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 77.32 |
| Support Level | $10.30 | $48.91 |
| Resistance Level | $11.57 | $55.47 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | -0.03 | -0.52 |
| Stochastic Oscillator | 42.75 | 100.00 |
Price Performance
Historical ComparisonAbout FSK FS KKR Capital Corp.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.